Design Therapeutics Inc. (NASDAQ: DSGN) Stock Information | RedChip

Design Therapeutics Inc. (NASDAQ: DSGN)


$6.3100
+0.1000 ( +1.45% ) 28.9K

Design Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the research and development of GeneTACTM molecules, which are a novel class of small-molecule gene-targeted chimera therapeutic candidates designed to be disease-modifying by addressing the underlying cause of diseases caused by inherited nucleotide repeat expansion mutations. The Company's product candidate is in Friedreich ataxia (FA), its second product candidate is in Fuchs endothelial corneal dystrophy (FECD), and it is also advancing its GeneTACTM program to address other serious nucleotide repeat-driven monogenic diseases.

Market Data


Open


$6.3100

Previous close


$6.2100

Volume


28.9K

Market cap


$347.37M

Day range


$6.1150 - $6.3490

52 week range


$2.2450 - $7.7700

SEC Filings


Form Type Description Pages Date
4 Insider transactions 1 Dec 19, 2024
10-q Quarterly Reports 60 Nov 07, 2024
8-k 8K-related 13 Nov 07, 2024
4 Insider transactions 1 Aug 12, 2024
8-k 8K-related 13 Aug 05, 2024
10-q Quarterly Reports 58 Aug 05, 2024
4 Insider transactions 1 Jun 17, 2024
4 Insider transactions 1 Jun 17, 2024
4 Insider transactions 1 Jun 17, 2024
8-k 8K-related 11 Jun 17, 2024

Latest News